Endo International PLC (NASDAQ:ENDP) (TSE:ENL) – Investment analysts at Oppenheimer Holdings lifted their Q3 2017 earnings estimates for shares of Endo International PLC in a research note issued to investors on Monday. Oppenheimer Holdings analyst D. Archila now anticipates that the company will earn $0.69 per share for the quarter, up from their prior forecast of $0.65. Oppenheimer Holdings currently has a “Hold” rating on the stock. Oppenheimer Holdings also issued estimates for Endo International PLC’s Q3 2018 earnings at $0.67 EPS, Q4 2018 earnings at $0.71 EPS, FY2018 earnings at $2.71 EPS and FY2019 earnings at $3.20 EPS.
ENDP has been the subject of a number of other research reports. William Blair restated a “market perform” rating on shares of Endo International PLC in a research note on Wednesday, June 14th. BidaskClub lowered Endo International PLC from a “hold” rating to a “sell” rating in a research note on Thursday, June 15th. Cantor Fitzgerald assumed coverage on Endo International PLC in a report on Friday, June 16th. They set a “neutral” rating and a $12.00 target price on the stock. Guggenheim assumed coverage on Endo International PLC in a report on Saturday, June 17th. They set a “hold” rating and a $12.00 target price on the stock. Finally, Deutsche Bank AG reduced their target price on Endo International PLC from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, July 7th. Three research analysts have rated the stock with a sell rating, fifteen have given a hold rating and six have given a buy rating to the company. Endo International PLC presently has a consensus rating of “Hold” and a consensus price target of $12.64.
Shares of Endo International PLC (NASDAQ:ENDP) opened at 8.98 on Thursday. Endo International PLC has a 1-year low of $7.41 and a 1-year high of $21.87. The company’s 50-day moving average price is $8.70 and its 200 day moving average price is $10.59. The stock’s market cap is $2.01 billion.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last posted its earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.19. The firm had revenue of $875.73 million during the quarter, compared to analysts’ expectations of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The firm’s revenue was down 4.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.86 earnings per share.
Several hedge funds have recently modified their holdings of the company. Piedmont Investment Advisors LLC increased its position in shares of Endo International PLC by 43.4% during the 2nd quarter. Piedmont Investment Advisors LLC now owns 59,211 shares of the company’s stock valued at $661,000 after purchasing an additional 17,928 shares during the period. Nomura Holdings Inc. acquired a new position in shares of Endo International PLC during the 2nd quarter valued at $745,000. Flinton Capital Management LLC increased its position in shares of Endo International PLC by 64.4% during the 2nd quarter. Flinton Capital Management LLC now owns 20,400 shares of the company’s stock valued at $228,000 after purchasing an additional 7,990 shares during the period. Bank of Hawaii acquired a new position in shares of Endo International PLC during the 2nd quarter valued at $180,000. Finally, Parametric Portfolio Associates LLC increased its position in shares of Endo International PLC by 18.7% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 398,099 shares of the company’s stock valued at $4,447,000 after purchasing an additional 62,822 shares during the period. Institutional investors own 90.71% of the company’s stock.
In other news, CEO Paul Campanelli purchased 6,500 shares of the stock in a transaction dated Monday, August 14th. The shares were bought at an average cost of $7.71 per share, for a total transaction of $50,115.00. Following the transaction, the chief executive officer now owns 213,620 shares in the company, valued at $1,647,010.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Terrance J. Coughlin purchased 20,000 shares of the stock in a transaction dated Thursday, August 10th. The shares were purchased at an average price of $7.70 per share, for a total transaction of $154,000.00. Following the completion of the transaction, the chief operating officer now owns 181,369 shares in the company, valued at approximately $1,396,541.30. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 36,000 shares of company stock worth $279,460. 0.50% of the stock is owned by insiders.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.